• Policy
• GOV·Pharma starts work to localize 57 essential medicines
• by Lee, Jeong-Hwan Sep 13, 2022 05:52am

• Company
• Hanmi’s Rolontis receives US FDA marketing approval
• by Kim, Jin-Gu Sep 13, 2022 05:52am

• Opinion
• [Reporter's view] PVA market should be actively reflected
• by Lee, Tak-Sun Sep 13, 2022 05:51am

• Policy
• Paxlovid is contraindicated with other concomitant meds
• by Lee, Tak-Sun Sep 13, 2022 05:51am

• InterView
• “Will rise independently as Organon in the industry”
• by Eo, Yun-Ho Sep 8, 2022 05:59am

• Company
• Unilateral voluntary retirement
• by Sep 8, 2022 05:59am

• Policy
• Approval of Boryung’s new SCLC drug Zepzelca imminent
• by Lee, Hye-Kyung Sep 8, 2022 05:58am

• Company
• Sales of immuno-cancer drugs exceeded 200 billion won
• by Sep 8, 2022 05:58am

• Company
• Zolgensma, which is the same price as an apartment
• by Moon, sung-ho Sep 8, 2022 05:58am

• Policy
• MOHW to provide premium pricing support for innovative drugs
• by Lee, Jeong-Hwan Sep 7, 2022 05:52am